{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:10:58Z","timestamp":1789528258332,"version":"build-2803163510"},"reference-count":15,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2015,9,14]],"date-time":"2015-09-14T00:00:00Z","timestamp":1442188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0136207","type":"journal-article","created":{"date-parts":[[2015,9,14]],"date-time":"2015-09-14T18:37:20Z","timestamp":1442255840000},"page":"e0136207","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Double Relapsed and\/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs"],"prefix":"10.1371","volume":"10","author":[{"given":"Sarah","family":"Gooding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Jun","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmy","family":"Dickens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ash","family":"Bullement","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Elvidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Ramasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,9,14]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/bjh.12465","article-title":"Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis","volume":"163","author":"S Pozzi","year":"2013","journal-title":"British journal of haematology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00520-013-1991-4","article-title":"Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study","volume":"22","author":"K Jordan","year":"2013","journal-title":"Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11899-013-0173-2","article-title":"Management of Double-Refractory Multiple Myeloma","volume":"8","author":"JP Meadows","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study","volume":"26","author":"SK Kumar","year":"2012","journal-title":"Leukemia"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10198-012-0395-6","article-title":"Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales","volume":"14","author":"RE Brown","year":"2013","journal-title":"Eur J Health Econ"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3111\/13696998.2012.760159","article-title":"Total cost comparison in relapsed\/refractory multiple myeloma","volume":"16","author":"B Durie","year":"2013","journal-title":"J Med Econ"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/jcpt.12020","article-title":"Real-world health care costs of relapsed\/refractory multiple myeloma during the era of novel cancer agents","volume":"38","author":"JG Gaultney","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.2012-0484","article-title":"Efficient allocation of novel agents in multiple myeloma: a work in progress","volume":"18","author":"JG Gaultney","year":"2013","journal-title":"The oncologist"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1634\/theoncologist.2012-0113","article-title":"Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data","volume":"18","author":"A Teitelbaum","year":"2013","journal-title":"The oncologist"},{"key":"ref10","first-page":"302","article-title":"Novel approaches to treatment of double-refractory multiple myeloma","author":"HC Lee","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"SV Rajkumar","year":"2011","journal-title":"Blood"},{"key":"ref12","article-title":"Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and\/or refractory to bortezomib and lenalidomide","author":"IJ Lau","year":"2014","journal-title":"Annals of hematology"},{"key":"ref13","unstructured":"Palumbo A, Davies F, Lee D, Dhanasiri S, Facon T, Zaki M, et al. Quality of life weights (utilities) in refractory or relapsed and refractory multiple myeloma (RRMM) patients using EORTC-8D and EQ-5D. Lymphoma and Myeloma 2013: An International Congress on Hematologic Malignancies 2013: Poster P-03."},{"key":"ref14","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1200\/JCO.2013.49.1845","article-title":"Cancer Drugs in the United States: Justum Pretium\u2014The Just Price","volume":"31","author":"HM Kantarjian","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"ref15","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013 6. The appraisal of the evidence and structured decision-making. 2013; Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/publications.nice.org.uk\/guide-to-the-methods-of-technology-appraisal-2013-pmg9\/the-appraisal-of-the-evidence-and-structured-decision-making\" xlink:type=\"simple\">http:\/\/publications.nice.org.uk\/guide-to-the-methods-of-technology-appraisal-2013-pmg9\/the-appraisal-of-the-evidence-and-structured-decision-making<\/ext-link>."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0136207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T19:40:23Z","timestamp":1588966823000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0136207"}},"subtitle":[],"editor":[{"given":"Sudeep","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,9,14]]},"references-count":15,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2015,9,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0136207","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,14]]}}}